Are patients willing to travel for better ovarian cancer care?

Slides:



Advertisements
Similar presentations
What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Advertisements

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre
Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.
Small-Cell Carcinoma in Association With a Mature Cystic Teratoma of the Ovary: A Case Report With Literature Review Karina E. Hew, Kimberley Studeman,
Nicoletta Colombo, Martin Gore 
Volume 144, Issue 1, Pages (January 2017)
Family Stress in Pediatric Critical Care
Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.
Volume 148, Issue 1, Pages (January 2018)
Volume 148, Issue 1, Pages (January 2018)
Volume 148, Issue 1, Pages (January 2018)
L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L
Volume 148, Issue 1, Pages (January 2018)
Volume 146, Issue 3, Pages (September 2017)
Volume 145, Issue 2, Pages (May 2017)
Vulvar intraepithelial neoplasia: Risk factors for recurrence
Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008]  Douglas.
Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients  David Schoemaker, Robert Black, Lynne.
Volume 147, Issue 1, Pages 3-10 (October 2017)
The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells
Volume 141, Issue 2, Pages (May 2016)
Pediatric Intensive Care Treatment of Uncontrolled Status Epilepticus
M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns
Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei 
Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum  E.E. Stevens, J.N. Bottsford-Miller,
Volume 152, Issue 1, Pages (January 2019)
Volume 142, Issue 3, Pages (September 2016)
National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence  J. Chino, J.R. Foote,
Volume 152, Issue 1, Pages (January 2019)
Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer  E.N. Prendergast,
K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Volume 143, Issue 2, Pages (November 2016)
Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base  A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,
The origins of multidisciplinary cancer care
Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)
Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM)  C. Popadiuk, A.J. Coldman,
I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M
Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum  A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,
Volume 152, Issue 1, Pages (January 2019)
Medical Care for Refugee Patients
Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates  N.A. Latif, E.M. Ko,
Volume 152, Issue 1, Pages (January 2019)
Volume 147, Issue 1, Pages (October 2017)
Volume 152, Issue 1, Pages (January 2019)
Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.
Antibiotic De-Escalation
The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough  K.M. Doll, E.L. Barber, J.T. Bensen,
Volume 142, Issue 2, Pages (August 2016)
Annika Idahl, Andrea Hermansson, Ann Lalos  Gynecologic Oncology 
Volume 152, Issue 1, Pages (January 2019)
Volume 130, Issue 1, Pages (July 2013)
Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.
Volume 152, Issue 1, Pages (January 2019)
Treatment of Colorectal Cancer
Volume 151, Issue 1, Pages (October 2018)
Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer  M. Dandapani, B.L. Seagle, R. Samuelson,
Volume 130, Issue 1, Pages (July 2013)
Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17]  Heini Lassus,
Volume 152, Issue 1, Pages (January 2019)
Volume 152, Issue 1, Pages (January 2019)
Volume 147, Issue 3, Pages (December 2017)
Volume 152, Issue 1, Pages (January 2019)
High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States  J.R.
Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma?  L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,
Donald Gardenier, Theresa Ullrich, Erin L. Davis 
Volume 115, Issue 1, Pages (October 2009)
Donald Gardenier, Theresa Ullrich, Erin L. Davis 
David Hubel and Torsten Wiesel
Presentation transcript:

Are patients willing to travel for better ovarian cancer care? David I. Shalowitz, Esther Nivasch, Robert A. Burger, Marilyn M. Schapira  Gynecologic Oncology  Volume 148, Issue 1, Pages 42-48 (January 2018) DOI: 10.1016/j.ygyno.2017.10.018 Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 1 Sample discrete choice experiment scenario. Gynecologic Oncology 2018 148, 42-48DOI: (10.1016/j.ygyno.2017.10.018) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 2 Percent willing to travel 50miles for given survival benefit (N=62). Gynecologic Oncology 2018 148, 42-48DOI: (10.1016/j.ygyno.2017.10.018) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 3 Percent willing to travel given distance for 6% survival benefit at 5years (N=55). Gynecologic Oncology 2018 148, 42-48DOI: (10.1016/j.ygyno.2017.10.018) Copyright © 2017 Elsevier Inc. Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.